Search results for "ASES"

showing 10 items of 26804 documents

Community-acquired febrile urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in hospitalised infants.

2015

Abstract Introduction Extended-spectrum beta-lactamase (ESBL) producing bacteria are infrequent pathogens of urinary tract infections in children. The objective of our study was to investigate the presence, clinically associated characteristics and risk factors for acquisition of urinary tract infection/acute pyelonephritis (UTI/APN) in hospitalised children Methods A case-control study in a second level community hospital in Spain, in which 537 episodes of UTI/APN were investigated in a retrospective study between November 2005 and August 2014. Cases were patients with ESBL strains. For each case, four ESBL-negative controls were selected. A questionnaire with the variables of interest was…

0301 basic medicineMalemedicine.medical_specialtyFevermedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticsHospitals CommunityComorbidityFosfomycinTazobactamVesicoureteral refluxMeropenembeta-Lactam Resistancebeta-Lactamases03 medical and health sciencesBacterial ProteinsRisk FactorsInternal medicineSurveys and Questionnairespolycyclic compoundsmedicineEscherichia coliHumansEscherichia coli InfectionsRetrospective StudiesVesico-Ureteral RefluxInpatientsPyelonephritisbusiness.industryInfantbiochemical phenomena metabolism and nutritionbacterial infections and mycosesmedicine.diseaseSurgeryCommunity-Acquired InfectionsSpainCase-Control StudiesUrinary Tract InfectionsBeta-lactamasebacteriaGentamicinFemalebusinessmedicine.drugPiperacillinEnfermedades infecciosas y microbiologia clinica
researchProduct

A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.

2019

Scope Gut microbiota contributes to non-alcoholic fatty liver disease (NAFLD) pathogenesis by multiple mechanisms not yet completely understood. Novel differential features between germ-free mice (GFm) transplanted with protective or non-protective cecal microbiota against NAFLD are investigated. Methods and results Gut microbiota composition, plasma, and fecal bile acids (BAs) and liver mRNAs are quantified in GFm recipients from four donor mice differing in NAFLD severity (control diet, high-fat diet [HFD]-responder, HFD-non-responder, and quercetin-supplemented HFD). Transplanted GFm are on control or HFD for 16-weeks. Multivariate analysis shows that GFm colonized with microbiota from H…

0301 basic medicineMalemedicine.medical_specialtyGut floraDiet High-Fatdigestive systemPathogenesisBile Acids and Salts03 medical and health sciencesMiceNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineAnimalsFeces030109 nutrition & dieteticsbiologyEthanoldigestive oral and skin physiologyFatty livernutritional and metabolic diseasesTransporterbiology.organism_classificationmedicine.diseasePhenotypeGastrointestinal MicrobiomeMice Inbred C57BL030104 developmental biologyEndocrinologyLiverBacteroidesTranscriptomeDrug metabolismFood ScienceBiotechnologyMolecular nutritionfood research
researchProduct

Sex-specific differences in genetic and nongenetic determinants of mean platelet volume: results from the Gutenberg Health Study.

2016

Mean platelet volume (MPV), a measure of platelet size, is a potential biological marker of platelet function. To date, a comprehensive analysis including known genetic and nongenetic factors that determine MPV is still lacking. MPV has been evaluated in 15 010 individuals from the population-based Gutenberg Health Study. Genetic information was available for 4175 individuals. Our results showed that age (β, 0.0346; 95% confidence interval [CI], 0.0255 to 0.0436), cardiovascular risk factors (CVRFs) such as smoking (β, 0.178; 95% CI, 0.128 to 0.229), hypertension (β, 0.05; 95% CI, 0.00289 to .0981), and high glucose level (β, 0.00179; 95% CI, 0.0006 to 0.00299) were linked with higher MPV i…

0301 basic medicineMalemedicine.medical_specialtyImmunologyPopulationSingle-nucleotide polymorphismDisease030204 cardiovascular system & hematologyBiochemistryGastroenterologyPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineSex FactorsPolymorphism (computer science)Risk FactorsInternal medicineGenetic variationMedicineHumansGenetic Predisposition to DiseaseGenetic variabilityMean platelet volumeeducationAgedGeneticseducation.field_of_studybusiness.industryAge FactorsThrombosisCell BiologyHematologyMiddle AgedConfidence interval030104 developmental biologyCardiovascular DiseasesFemalebusinessMean Platelet VolumeBlood
researchProduct

Functional Improvement after Photothrombotic Stroke in Rats Is Associated with Different Patterns of Dendritic Plasticity after G-CSF Treatment and G…

2016

We have previously shown that granulocyte-colony stimulating factor (G-CSF) treatment alone, or in combination with constraint movement therapy (CIMT) either sequentially or concomitantly, results in significantly improved sensorimotor recovery after photothrombotic stroke in rats in comparison to untreated control animals. CIMT alone did not result in any significant differences compared to the control group (Diederich et al., Stroke, 2012;43:185-192). Using a subset of rat brains from this former experiment the present study was designed to evaluate whether dendritic plasticity would parallel improved functional outcomes. Five treatment groups were analyzed (n = 6 each) (i) ischemic contr…

0301 basic medicineMalemedicine.medical_specialtyLightmedicine.medical_treatmentMovement10208 Institute of NeuropathologyIschemialcsh:Medicine610 Medicine & health1100 General Agricultural and Biological Sciences03 medical and health sciences0302 clinical medicine1300 General Biochemistry Genetics and Molecular BiologyInternal medicineNeuroplasticityGranulocyte Colony-Stimulating FactormedicineAnimalscardiovascular diseasesRats Wistarlcsh:ScienceSalineStrokePhysical Therapy Modalities1000 MultidisciplinaryMultidisciplinaryNeuronal Plasticitybusiness.industryPyramidal Cellslcsh:RDendritesRecovery of Functionmedicine.diseaseCombined Modality TherapyCortex (botany)SurgeryGranulocyte colony-stimulating factorConstraint-induced movement therapyStroke030104 developmental biologyEndocrinologyConcomitant570 Life sciences; biologylcsh:Qbusiness030217 neurology & neurosurgeryResearch ArticlePLoS ONE
researchProduct

Genetic and constitutional factors are major contributors to substantia nigra hyperechogenicity

2017

9 páginas, 2 figuras, 4 tablas

0301 basic medicineMalemedicine.medical_specialtyMovement disordersScienceSubstantia nigraDiseaseComorbidityArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansGenetic Predisposition to DiseaseFamily historyAmyotrophic lateral sclerosisPsychiatryGenetic Association StudiesGenetic testingAgedUltrasonographyMultidisciplinarymedicine.diagnostic_testbusiness.industryQCase-control studyRNeurodegenerative DiseasesMiddle Agedmedicine.diseaseComorbiditySubstantia Nigra030104 developmental biologyCase-Control StudiesMutationMedicineFemalemedicine.symptombusiness030217 neurology & neurosurgeryBiomarkers
researchProduct

Proinflammatory and amyloidogenic S100A9 induced by traumatic brain injury in mouse model.

2019

Traumatic brain injury (TBI) represents a significant risk factor for development of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The S100A9-driven amyloid-neuroinflammatory cascade occurring during primary and secondary TBI events can serve as a mechanistic link between TBI and Alzheimer’s as demonstrated recently in the human brain tissues. Here by using immunohistochemistry in the controlled cortical impact TBI mouse model we have found pro-inflammatory S100A9 in the brain tissues of all mice on the first and third post-TBI days, while 70% of mice did not show any S100A9 presence on seventh post-TBI day similar to controls. This indicates that defensive mechanisms effe…

0301 basic medicineMalemedicine.medical_specialtyNeurologyAmyloidTraumatic brain injuryPlaque AmyloidProtein Aggregation PathologicalS100A9Proinflammatory cytokine03 medical and health sciencesMice0302 clinical medicineBrain Injuries TraumaticmedicineAnimalsCalgranulin BSignificant riskNeuroinflammationNeuronsbusiness.industryGeneral NeuroscienceBrainmedicine.diseasenervous system diseasesDisease Models Animal030104 developmental biologyMicrogliabusinessAlzheimer’s disease Amyloid Neuroinflammation Oligomerization S100A9 Traumatic brain injuryNeuroscience030217 neurology & neurosurgeryNeuroscience letters
researchProduct

Loop diuretics decrease the renal elimination rate and increase the plasma levels of trimethylamine‐N‐oxide

2018

Aims Trimethylamine-N-oxide (TMAO) is a novel cardiovascular risk marker. We explored the association of commonly used cardiovascular medications with TMAO levels in patients and validated the identified associations in mice. Methods Detailed history of drug treatment was recorded in 300 patients with cardiovascular disease without diabetes in an observational, cross-sectional study. Animal study was performed in CD1 mice. Results Median plasma TMAO (interquartile range) level was 2.144 (1.570-3.104) μmol l-1 . Among nine cardiovascular drug groups, the use of loop diuretics (0.510 ± 0.296 in users vs. 0.336 ± 0.272 in nonusers, P = 0.008) and mineralocorticoid receptor antagonists (0.482 ±…

0301 basic medicineMalemedicine.medical_specialtyOrganic anion transporter 1medicine.drug_classTrimethylamine N-oxide030204 cardiovascular system & hematologyKidneyExcretion03 medical and health scienceschemistry.chemical_compoundMethylaminesMice0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsInternal medicineBlood plasmamedicineAnimalsHumansPharmacology (medical)AgedPharmacologybiologyChemistryArea under the curveFurosemideCardiovascular AgentsHeartOriginal ArticlesLoop diureticMiddle AgedProbenecid030104 developmental biologyEndocrinologyCross-Sectional StudiesLiverCardiovascular Diseasesbiology.proteinFemaleBiomarkersmedicine.drug
researchProduct

Lysosomal acid lipase deficiency: Expanding differential diagnosis.

2016

The differential diagnoses for metabolic liver diseases may be challenging in clinical settings, which represents a critical issue for disorders such as lysosomal acid lipase deficiency (LAL-D). LAL-D is caused by deficient activity of the LAL enzyme, resulting in the accumulation of cholesteryl esters and triglycerides throughout the body, predominately in the liver, spleen, gastrointestinal tract, and blood vessel walls. LAL-D is a progressive, multi-organ disease with early mortality and significant morbidity characterized by a combination of hepatic dysfunction and dyslipidemia. Evidence suggests LAL-D may be substantially underdiagnosed or misdiagnosed, which is critical given that dis…

0301 basic medicineMalemedicine.medical_specialtyPathologyAdolescentEndocrinology Diabetes and MetabolismDiseaseLysosomal acid lipase deficiencyBiochemistryGastroenterologyDiagnosis Differential03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineGeneticsmedicineLysosomal storage diseaseHumansChildMolecular BiologyTriglyceridesNiemann-Pick DiseasesGaucher Diseasebusiness.industryWolman DiseaseInfantEnzyme replacement therapySterol Esterasemedicine.diseaseClinical trial030104 developmental biologyEarly DiagnosisSebelipase alfaDisease Progression030211 gastroenterology & hepatologyFemaleCholesterol EstersDifferential diagnosisbusinessDyslipidemiaMolecular genetics and metabolism
researchProduct

Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real‐life setting: the PROSISA Study

2021

Aim: Statin-associated muscle symptoms (SAMS) are a major determinant of poor treatment adherence and/or discontinuation, but a definitive diagnosis of SAMS is challenging. The PROSISA study was an observational retrospective study aimed to assess the prevalence of reported SAMS in a cohort of dyslipidaemic patients. Methods: Demographic/anamnestic data, biochemical values and occurrence of SAMS were collected by 23 Italian Lipid Clinics. Adjusted logistic regression was performed to estimate odds ratio (OR) and 95% confidence intervals for association between probability of reporting SAMS and several factors. Results: Analyses were carried out on 16 717 statin-treated patients (mean ± SD, …

0301 basic medicineMalemedicine.medical_specialtySettore MED/09 - Medicina Internaadverse effects; myopathy; statin-associated muscle symptoms; statinsstatin-associated muscle symptomsadverse effects; myopathy; statin-associated muscle symptoms; statins.030204 cardiovascular system & hematologystatinsMedication Adherence03 medical and health sciences0302 clinical medicineMuscular DiseasesInternal medicineadverse effectInternal MedicinemedicinePrevalencestatins.Humansstatin‐associated muscle symptomsAdverse effectDechallengeadverse effects; myopathy; statin-associated muscle symptoms; statins; Creatine Kinase; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Medication Adherence; Middle Aged; Muscular Diseases; Prevalence; Retrospective StudiesCreatine KinaseDyslipidemiasRetrospective Studiesbusiness.industryRetrospective cohort studyOdds ratioOriginal ArticlesMiddle AgedConfidence intervalDiscontinuation030104 developmental biologyItalyConcomitantCohortadverse effectsOriginal ArticleFemaleHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessstatin-associated muscle symptommyopathyJournal of Internal Medicine
researchProduct

Short-term Changes in Gal 3 Circulating Levels After Acute Myocardial Infarction.

2016

Background and Aims Galectin 3 (Gal 3) is a β-galactoside-binding lectin known to play a part in inflammation, adverse remodeling and fibrosis. Gal 3 seems to be linked to atherogenesis and Coronary Artery Disease (CAD), but less is known about the relationship between Gal 3 and acute myocardial infarction (AMI). The aim of the present study is to assess circulating levels of Gal 3 after AMI and to evaluate short-term changes of the biomarker within 5 days from the acute event. Methods Two hundred fifteen confirmed AMI patients (125 STEMI, M/F = 2.8; mean age: 65.4 ± 13.8 years) were enrolled in the present study; two blood samples were collected from each patient: first, within 1 h from ad…

0301 basic medicineMalemedicine.medical_specialtyTime FactorsGalectin 3Myocardial InfarctionInflammationCoronary Artery Disease030204 cardiovascular system & hematologyAMICoronary artery disease03 medical and health sciences0302 clinical medicineFibrosisInternal medicineMedicineHumansCADcardiovascular diseasesMyocardial infarctionPlaqueAgedInflammationbusiness.industryMedicine (all)Mean ageGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyGalectin-3ImmunologyCardiologyBiomarker (medicine)Femalemedicine.symptombusinessBiomarkersArchives of medical research
researchProduct